Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACP1 | P24666 | 9/20 | 0.44 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.43 |
| ▸ | ATR | Q13535 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23015198 | 1.00 | ACP1 (0.44) | ACP1SLC2A1ATRALDH1A1KDM4E | |
| SCHEMBL23015131 | 0.92 | SLC2A1 (0.51) | ACP1SLC2A1ALDH1A1KDM4ELMNA | |
| SCHEMBL29636834 | 0.92 | SLC2A1 (0.51) | ACP1SLC2A1ALDH1A1KDM4ELMNA | |
| SCHEMBL28967194 | 0.90 | ACP1 (0.49) | ACP1SLC2A1PDE10A | |
| Trifluoroacetic Acid SCHEMBL29636818 | 0.83 | ACP1 (0.47) | ACP1SLC2A1 | |
| SCHEMBL23029676 | 0.82 | ACP1 (0.51) | ACP1SLC2A1ALDH1A1KDM4E | |
| SCHEMBL23015171 | 0.82 | ACP1 (0.47) | ACP1SLC2A1MAPT | |
| SCHEMBL29636793 | 0.82 | ACP1 (0.47) | ACP1SLC2A1MAPT | |
| SCHEMBL26967698 | 0.82 | MAPT (0.47) | SLC2A1ALDH1A1KDM4ELMNAGAA | |
| SCHEMBL23015284 | 0.80 | EHMT2 (0.59) | SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4017492-A1 | MOLECULES THAT BIND TO TDP-43 FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS AND RELATED DISORDERS | Biohaven Therapeutics Ltd. (US) | 2022-06-29 | — | — | EP | disclosed |